New cancer vaccine aims to fight advanced tumors when other treatments fail
NCT ID NCT06541639
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a cancer vaccine called EVM16, either by itself or combined with an immune-boosting drug (tislelizumab), in people with advanced or recurrent solid tumors that have not responded to standard treatments. The main goals are to find a safe dose and see if the vaccine triggers an immune response against the cancer. The trial involves about 78 participants and will monitor side effects and any tumor shrinkage.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- EVM16 (cancer vaccine) and tislelizumab (anti-PD-1 antibody)
- What this could lead to
- If successful, this approach could offer a new treatment option for people with advanced solid tumors who have run out of standard therapies.
- What could go wrong
- This is an early-phase trial with a small number of participants, so the vaccine may not prove effective or may cause unexpected side effects. The results may not apply to all tumor types.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED OR RECURRENT SOLID TUMORS are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Beijing Cancer Hospital
RECRUITINGBeijing, Beijing Municipality, 100142, China
-
Fudan University Shanghai Cancer Center
RECRUITINGShanghai, Shanghai Municipality, 200135, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.